SCHEMBL5534115

SCHEMBL5534115

C#Cc1ccc(NC(=O)c2cc(OC)ccc2N(C=O)c2ccc(C=NN3CCC3)cc2F)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
F10 P00742 10/20 0.34
KCNH2 Q12809 3/20 0.34
KMT2A Q03164 2/20 0.34
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
F2 P00734 3/20 0.32
F9 P00740 2/20 0.32
PRSS1 P07477 2/20 0.32
PRSS2 P07478 2/20 0.32
F7 P08709 2/20 0.32
PRSS3 P35030 2/20 0.32
FGFR4 P22455 2/20 0.32
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5533803 0.88 F10 (0.38) NPC1RAB9AMITFTP53GAA
SCHEMBL5534413 0.86 F10 (0.37) NPC1RAB9AF10KCNH2KMT2A
SCHEMBL5529930 0.85 F10 (0.35) NPC1RAB9AMITFTP53GAA
SCHEMBL5531803 0.85 F10 (0.36) NPC1RAB9AMITFTP53GAA
SCHEMBL5531647 0.82 NPC1 (0.38) NPC1RAB9ATP53F10KCNH2
SCHEMBL5531693 0.78 FGFR4 (0.38) NPC1RAB9AMITFTP53GAA
SCHEMBL5531606 0.77 F10 (0.47) NPC1RAB9AF10KCNH2FGFR4
SCHEMBL5532013 0.76 MEN1 (0.38) NPC1RAB9ATP53GAAF10
SCHEMBL5528410 0.76 F10 (0.37) NPC1RAB9AF10KMT2ACYP2C9
SCHEMBL5532157 0.76 F10 (0.43) F10KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US claimed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 NPC1 2635/4885RAB9A 1933/4885MITF 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.